NCT01207102View on ClinicalTrials.gov

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Abraxane

Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days

DRUG

Carboplatin

area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days

Trial Locations (2)

27710

Duke University Medical Center, Durham

100142

Peking University School of Oncology/Beijing Cancer Hospital, Beijing

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Duke University

OTHER